Human copper transporter 1 (hCtr1) has been convincingly demonstrated to transport cisplatin and its analogues. We investigated the prognostic value of hCtr1 expression in cervical cancer patients treated with definitive platinum-based concurrent chemoradiotherapy. We identified 119 consecutive patients with FIGO stages IB to IVA cervical cancer who had received definitive platinum-based concurrent chemoradiotherapy. Immunohistochemical studies of the formalin-fixed, paraffin-embedded tissues were performed. The cliniopathologic features, patterns of treatment failure, and survival data for all patients were collected. Univariate and multivariate analyses were performed to determine the prognostic factors that influenced patient survival. Median follow-up time was 5.5 years (range, 1.5 to 23.5 years). Positive immunostainings of hCtr1 were observed in 46 (39%) out of 119 patients. There were no differences on age, FIGO stage and histologic types between patients with hCtr1-positive and negative tumors. Patients with hCtr1-positive tumors had a significantly better disease-free survival (DFS) than hCtr1-negative tumors. The 5-year DFS was 72.2% for patients with hCtr1-positive tumor, compared to 48.8% for patients with hCtr1-negative tumor (P = 0.03). Multivariate analyses revealed that positive hCtr1 (hazard ratio [HR], 0.47, 95% CI: 0.25 to 0.89), FIGO stage (HR: 0.31, 95% CI: 0.17-0.56) and brachytherapy (HR: 0.23, 95% CI: 0.11-0.50) were independent significant prognostic factors for DFS. Overexpression of hCtr1 is an independent prognostic factor in cervical cancer patients receiving platinum-based concurrent chemoradiotherapy.